Diagnostic and Therapeutic Research

Mammastatin was first described in the journal Science as a tissue-specific growth-inhibitory protein that inhibited the growth of breast cancer cells. The Mammastatin Serum Assay was subsequently developed as a diagnostic test for assessing breast cancer risk and early detection. The breast cancer inhibition effects of mammastatin were confirmed during in vivo Compassionate Use studies when an early therapeutic preparation of mammastatin was administered to palliative Stage IV women with breast cancer.

Abviva’s research interests are directed toward innovating and developing breast cancer diagnostic and breast cancer therapeutic products that can benefit individuals throughout the world. Abviva intends to conduct basic, translational and clinical research with biotechnology, pharmaceutical and leading university and government institutions world wide through internal and external collaborative research. We intend that research conducted on mammastatin will advance the knowledge and understanding of the biological mechanisms underlying the mammastatin phenomenon as well as advance the scientific, medical, diagnostic and therapeutic understanding of mammastatin and breast cancer.